Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/278266 
Erscheinungsjahr: 
2022
Schriftenreihe/Nr.: 
Research Paper No. 169
Verlag: 
South Centre, Geneva
Zusammenfassung: 
The 12th WTO Ministerial Conference adopted a Ministerial Decision on the TRIPS Agreement on 17 June 2022. This partially concluded almost two years of protracted discussions in response to a proposal by India and South Africa for a waiver from certain obligations under the TRIPS Agreement for health products and technologies for the prevention, treatment and containment of COVID-19. The adopted Decision only waives the obligation under article 31 (f) of the TRIPS Agreement. Developing country WTO members are now allowed to export any proportion of vaccines, including ingredients and processes, necessary for the COVID-19 pandemic that are manufactured under a compulsory license or government use authorization to other developing countries. It also contains some clarifications of relevant TRIPS provisions, while introducing a number of conditionalities that are not present in the TRIPS Agreement. This paper examines the object and scope of the Decision, the requirements established for its use, and the required actions to be taken by WTO members to implement it.
Schlagwörter: 
Compulsory Licenses
COVID-19
Diagnostics
Dispute Settlement
Doha Declaration on the TRIPS Agreement and Public Health
Flexibilities
Government Use
MC12
Pandemic
Parallel Importation
Test Data
Therapeutics
TRIPS
TRIPS Agreement
TRIPS Flexibilities
TRIPS Waiver
Vaccines
Voluntary License
World Trade Organization (WTO)
WTO TRIPS Decision on COVID-19 Vaccines
Dokumentart: 
Research Report
Erscheint in der Sammlung:

Datei(en):
Datei
Größe
4.99 MB





Publikationen in EconStor sind urheberrechtlich geschützt.